Title: Sanofi-aventis Received from the FDA an Approvable Letter for Rimonabant for Weight Management and a Non Approvable Letter for Smoking Cessation
|
|
To print: Select File and then Print from your browser's menu Title: Sanofi-aventis Received from the FDA an Approvable Letter for Rimonabant for Weight Management and a Non Approvable Letter for Smoking Cessation |
|
"Sanofi-aventis Received from the FDA an Approvable Letter for Rimonabant for Weight Management and a Non Approvable Letter for Smoking Cessation" PARIS, FRANCE -- February 20, 2006 -- Sanofi-aventis announced today that it has received from the U.S. Food and Drug Administration (FDA), Division of Metabolism and Endocrinology Products an approvable letter for rimonabant for weight management, and from the Division of Anesthesia, Analgesia and Rheumatology Products a non approvable letter for smoking cessation. Sanofi-aventis will continue to work in close collaboration with the FDA. Rimonabant is the first in a new class of therapeutic agents called CB(1) blockers. SOURCE: sanofi-aventis |
|
Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. Go back This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 2009 P\S\L Consulting Group Inc. All rights reserved. |